1. Introduction
===============

For relatively invasive upper gastrointestinal endoscopy procedures, such as an endoscopic retrograde cholangiopancreatography (ERCP), and also lower gastrointestinal endoscopy procedures, anesthesia is routinely used to reduce patient anxiety. However, with the use of intravenous anesthesia, even at mild to moderate depth of anesthesia, there is always a risk of upper airway obstruction due to a relaxation of the upper airway muscles. "Guidelines on sedation in endoscopic practice" report on respiratory depression during an ERCP, and how it relates to sedation.^\[[@R1],[@R2]\]^ It has been reported that the frequently used deep sedation method of 4 to 5 mg of midazolam and 70 to 100 mg of pethidine hydrochloride during an ERCP, is associated with the occurrence of respiratory depression at rates as high as 85%.^\[[@R3]\]^

Interestingly, it has been reported that respiratory complications that occur during intravenous sedation have a higher risk of hypercapnia than hypoxemia.^\[[@R1],[@R4]--[@R7]\]^

Moreover, when low-flow oxygen is administered through a nasal cannula, the apparent percutaneous oxygen saturation value is maintained at a normal concentration; however, hypoventilation is sustained, which may result in impaired exhalation. The conditions of a gradual CO~2~ accumulation, and also CO~2~ concentrations maintained at 60 mm Hg or higher, are risk factors for secondary circulatory abnormalities such as an abnormal increase in blood pressure, tachycardia, and arrhythmia.

Furthermore, in recent years, the method of conventional air insufflation into the intestine during an ERCP, has been widely replaced by insufflating CO~2~ instead. It has been speculated that intestinal CO~2~ insufflation might reduce patient pain. However, it has been reported that CO~2~ in the intestinal tract is transiently absorbed into the bloodstream, and due to this observation, it is necessary to monitor patients for hypercapnia. In a study in which transcutaneous CO~2~ (PtcCO~2~) was measured during an ERCP,^\[[@R4]\]^ cases in which sedation was adjusted using PtcCO~2~ as an index during treatment were more likely to have PtcCO~2~ values exceeding 40 mm Hg.

Therefore, it is extremely important to monitor and prevent transient or continuous CO~2~ accumulation under intravenous sedation to maintain safe respiratory management.

A candidate to further improve respiratory management under intravenous anesthesia, is the use of a device called nasal high flow (NHF), which provides humidified air to flow to the nasal cavity at a high flow rate. NHF is typically used in patients with obstructive sleep apnea syndrome and respiratory disorders. This device has begun to be widely applied to the prevention of hypoxemia. It has a mild positive pressure load (several cmH~2~O) that improves respiratory function in part by improving CO~2~ wash out and reducing CO~2~ rebreathing.^\[[@R8]--[@R10]\]^ In addition, most recently, improved respiratory management using NHF is being studied during the propofol sedation.^\[[@R11]\]^ The hypothesis is that NHF use could prevent and resolve the onset of hypercapnia associated with transient upper airway obstruction during procedural sedation.

The purpose of this study was to maintain upper airway patency by applying NHF as a respiratory management method during intravenous anesthesia to patients undergoing ERCP performed under intravenous anesthesia. In addition, this study investigates whether improving respiratory management could prevent intraoperative hypercapnia and hypoxemia.

2. Methods/design
=================

2.1. Study design
-----------------

The present study was designed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials and Consolidated Standard of Reporting Trials 2010 guidelines.^\[[@R12],[@R13]\]^

This was an open-label, investigator-initiated, single center study on the efficacy of NHF use in patients undergoing ERCP performed under intravenous anesthesia. Treatment schedule and outcome measures are shown in Table [1](#T1){ref-type="table"}.
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The Clinical Research Review Board in Nagasaki University approved the study and study protocol. The study was conducted at Nagasaki University Hospital in Japan. The study is registered on the jRCTs. The study was conducted in accordance with the principles of the Declaration of Helsinki and the established best clinical practices of Japan.

2.2. Participant recruitment
----------------------------

Participants were recruited from the Nagasaki University Hospital, where the subsequent study also took place. The treating clinical research coordinator (CRC) provided an explanation of the study to all participants, and these participants signed an informed consent form.

This was a randomized control study, comprised of 2 groups of participants. While both groups received intravenous anesthesia during ERCP, 1 group concomitantly used an NHF device.

After giving consent, subjects who met the registration requirements were randomly assignment to one of the 2 groups. Fifty-percent of patients are randomly assigned to each group.

2.3. Inclusion criteria
-----------------------

The following were inclusion criteria: adult patients between the ages of 20 and 85, that gave informed consent after a thorough explanation of all details of this clinical trial.

2.4. Exclusion criteria
-----------------------

The exclusion criteria were as follows:

1.  continuous administration of oxygen by nasal cannula (home oxygen therapy),

2.  inability to breathe through the nose,

3.  use of antithrombotic drugs that could not be reduced or discontinued on the day before the endoscope,

4.  a history of pneumothorax,

5.  judged inappropriate as study subjects.

2.5. Study protocol
-------------------

All participants underwent an ERCP under intravenous sedation, in a supine position on an examination table, in an endoscope room. Patients assigned to the NHF device group were cannulated with NHF in both nasal passages and provided with humidified air at a flow rate of 40 to 60 L/min.

A blood pressure monitor, electrocardiogram, and percutaneous oxygen saturation probe attached to the finger were used at the time of examination and treatment. Moreover, a transcutaneous CO~2~ probe was attached to the anterior chest or medial arm, and vital signs were continuously monitored. In order to continuously and non-invasively evaluate the circulating CO~2~ concentration, a transcutaneous CO~2~ concentration that was not affected even when inhaling high flow air with a nasal cannula was used. Transcutaneous CO~2~ was measured by a continuously attached electrode of the transcutaneous CO~2~ monitor (TCM) (Radiometer Inc., Japan) to the anterior chest and measuring the transcutaneous CO~2~ concentration together with the transcutaneous oxygen saturation and respiratory rate. Values were obtained from the anesthesia record of the electronic medical record (Nihon Kohden Inc., Japan). In the group receiving NHF, the values of vital signs 10 minutes after inhalation from the nasal cannula were recorded.

In the detection of the respiratory waveform, the respiratory phase, and the respiratory rate were evaluated based on the change in impedance between the electrodes using the three-electrode standard lead of the electrocardiogram.

To evaluate efficacy of NHF in the prevention of hypercapnia, the TCM output was used. PtcCO~2~ concentrations of 60 mm Hg or more (PaCO~2~ \> 55 mm Hg) were considered marked hypercapnia. PtcCO~2~ concentrations of 50 to 60 mm Hg (equivalent to PaCO~2~ \> 45 mm Hg) were considered moderate hypercapnia. Furthermore, the incidence of hypoxemia with a transcutaneous oxygen saturation value of 90% or less was evaluated. Results of these parameters determined whether the use of the NHF was effective in preventing the development of hypercapnia and hypoxemia.

Another parameter of the study that was assessed was the respiratory rate, evaluated by the change in impedance of an electrocardiographic (ECG) electrode. The depth of anesthesia was evaluated using the Ramsay scale, along with the total dose of the anesthetic and its dose per time.

In the NHF device group, patients used AIRVO2 (manufactured by Fisher & Paykel Healthcare) to inhale humidified air at a flow rate of 40 to 60 L/min from a nasal cannula.

2.6. Adverse events
-------------------

In this study, the NHF device was secured to the patient via a nasal cannula, and this might have felt uncomfortable. Moreover, an electrode for transcutaneous carbon dioxide concentration measurements was attached to the anterior chest for both the NFH group and non-NHF group. For participants with sensitive skin, this might have caused temporary redness. When these adverse events occurred, care was taken to prevent undue harm to the research subjects.

2.7. Outcome
------------

The primary endpoint was:

1.  the occurrence rate of severe hypercapnia with a maximum transcutaneous CO~2~ concentration of 60 mm Hg or more (equivalent to PaCO~2~ \> 55 mm Hg) during intravenous sedation,

2.  area under the curve of percutaneous CO~2~ concentration per unit time during intravenous anesthesia (AUC),

3.  duration of moderate hypercapnia showing maximum transcutaneous CO~2~ concentration of 50 mm Hg or more (equivalent to PaCO~2~ \> 45 mm Hg) during intravenous sedation,

4.  Occurrence rate of hypoxemia with percutaneous oxygen saturation value of 90% or less during intravenous sedation.

2.8. Efficacy
-------------

We evaluated the efficacy of the investigational device on a number of parameters, including: changes in CO~2~ concentration during treatment, the rate of occurrence of marked hypercapnia in which the maximum value of transcutaneous CO~2~ concentration is 60 mm Hg or more (equivalent to PaCO~2~ \> 55 mm Hg), and the duration of moderate hypercapnia as defined by a transcutaneous CO~2~ concentration of 50 to 60 mm Hg (equivalent to PaCO~2~ \> 45 mm Hg). Additionally, the incidence of hypoxemia was evaluated as defined by a transcutaneous oxygen saturation value of 90% or lower.

2.9. Safety
-----------

The safety evaluation indices of this clinical trial are as follows: adverse events are any undesired or unintended signs (including abnormal laboratory values, abnormal vital signs), symptoms, or illnesses that occur between the start of medical device (NHF) use and the end of the last observational study. This does not matter whether the study has a causal relationship. Symptoms and diseases occurring before the use of medical devices are treated as complications and not adverse events. However, if the complications worsen after the date of starting medical device use, they will be treated as adverse events, and the day on which the deterioration is confirmed will be the date of occurrence of the adverse events.

2.10. Data collection and management
------------------------------------

The assignment table and input table used in this study were created with Research Electronic Data Capture (REDCap). The study was conducted after allocating the registered patients, and the data of all items in the medical record collected in the study were assigned to the researcher assigned the ID entered by physician, co-doctor and co-worker. The Principal Investigator or Co-Researcher approved the input observation/inspection/evaluation data of each research subject immediately after confirming the content.

For the data entered in the case report, the Principal Investigator and the Clinical Research Center Data Management staff perform a visual check and a logical check. Consequent to each check, if there are any problems or doubts in the data, the principal investigator, or the research coordinator is contacted. The case is fixed by performing data lock on the case when the issue has been resolved, and any modifications have been completed. If there is an error that needs to be corrected after the case is locked, the data management staff is responsible for overseeing this process.

In this study, monitoring will be carried out in accordance with the research plan and monitoring procedures to ensure that the research is being conducted properly.

2.11. Statistical analysis
--------------------------

Since this study is exploratory, we estimated an incidence rate for each study parameter and then used this information to calculate the necessary sample size for the verification study to achieve statistical significance.

Specifically, the rate of occurrence of hypercapnia in the NHF device group and the control group was calculated, and the difference (ratio) between the 2 groups and the 95% confidence interval on both sides were calculated. For other items, the average value and standard deviation for each group were manually calculated.

3. Discussion
=============

The goal of using an NHF device, during an ERCP under intravenous anesthesia, was to prevent not only acute hypercapnia, but also hypoxemia. The clinical conditions resulting from a transient upper airway obstruction that can occur during intravenous anesthesia could be prevented or ameliorated by the use of an NHF device. It has been reported that the frequently used intravenous anesthesia during an ESD is associated with the higher occurrence rate of respiratory depression.^\[[@R3]\]^ Furthermore, it has been reported that respiratory complications that occur during intravenous anesthesia have a higher risk of hypercapnia than hypoxemia.^\[[@R1],[@R4]--[@R7]\]^ Therefore, the prevention of hypercapnia could be important factor for achieving safe respiratory management during procedural sedation for ESD.

This is an exploratory study aimed at collecting information for conducting a verification study. Therefore, the number of cases is set based on the feasibility in our hospital. About 250 patients undergoing ERCP under intravenous anesthesia at Nagasaki University Hospital for 1 year. Approximately 125 cases, of which consent can be obtained from about 125 cases with a data collection period of 6 months, would be about 80 cases. The 80 ERCP cases are assigned to 2 groups, a device use group (40 cases) and a non-use group (40 cases), and stratified (20 cases each) by an assignment factor (COPD severity). Furthermore, the incidence of hypercapnia in the target population is estimated to be around 10% to 20%. For this reason, the number of events in each group was 40 cases, and the possibility of generating more than 1 event would be increased.

The primary endpoint of this study was:

1.  the occurrence rate of severe hypercapnia with a maximum transcutaneous CO~2~ concentration of 60 mm Hg or more (equivalent to PaCO~2~ \> 55 mm Hg) during intravenous sedation,

2.  area under the curve of percutaneous CO~2~ concentration per unit time during intravenous anesthesia (AUC),

3.  duration of moderate hypercapnia showing maximum transcutaneous CO~2~ concentration of 50 mm Hg or more (equivalent to PaCO~2~ \> 45 mm Hg) during intravenous sedation,

4.  occurrence rate of hypoxemia with percutaneous oxygen saturation value of 90% or less during intravenous sedation.

In addition, the evaluation of depth of anesthesia using Ramsay scale and total anesthetic dose during sedation will be also be assessed as a secondary endpoint.

Schumann et al reported that the availability to use NHF during sedation in an endoscopy suite reduced the requirement for anesthesia to perform complex endoscopic procedures.^\[[@R14]\]^ NHF reduces the rebreathing of expired CO~2~ from the anatomical dead space, which allows for maintained gas exchange at a lower minute ventilation.^\[[@R15]\]^ Therefore, patients can achieve the same alveolar ventilation with a reduced workload for the respiratory muscles.^\[[@R16]\]^

The most recent our study indicated that during sedation with propofol, NHF without supplemental oxygen attenuates CO~2~ retention and reduces the respiratory rate.^\[[@R11]\]^ The findings suggest that NHF can improve ventilation during procedural sedation for relatively invasive upper gastrointestinal endoscopy procedures, such as an endoscopic retrograde cholangiopancreatography, and also lower gastrointestinal endoscopy procedures, which may reduce the risk of complications related to hypoventilation.

Acknowledgments
===============

The authors would like to thank our colleagues and staff at the Dental Anesthesiology, Gastroenterology and Hepatology Department of Nagasaki University Hospital for their support.

Author contributions
====================

TA, TS, GM, SK, NH, and SN are responsible for conceiving and designing the trial, planning data analysis, drafting the manuscript, and approving the final manuscript. MP and ST are responsible for preparing and completing set up of AIRVO device including all equipment. EO, HS, NK, and KO will participate in data collection and are in charge of recruitment and treatment of patients. All authors will have access to the interim results as well as the capacity to discuss, revise, and approve the final manuscript.

Abbreviations: ERCP = endoscopic retrograde cholangiopancreatography, NHF = nasal high flow, PtcCO~2~ = transcutaneous CO~2~, TCM = transcutaneous CO~2~ monitor.

How to cite this article: Ayuse T, Sawase H, Ozawa E, Nagata K, Komatsu N, Sanuki T, Kurata S, Mishima G, Hosogaya N, Nakashima S, Pinkham M, Tatkov S, Kazuhiko N. Study on prevention of hypercapnia by Nasal High Flow in patients undergoing endoscopic retrograde cholangiopancreatography during intravenous anesthesia. *Medicine*. 2020;99:19(e20036).

The trial started on October 25, 2019 and currently recruiting.

The Clinical Research Review Board in Nagasaki University approved the study and study protocol. Any modification to the protocol will be immediately communicated to all responsible authorities. All patients, or their legal representative, must give written informed consent before the study.

Results obtained in this trial will be published in an international journal and may be presented at international scientific meeting. This will be included in the patient consent form.

Only the designated trial investigators will have access to the personal data of participants and to the final data set. The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

The AIRVO device and the AIRVO information were provided by Fisher & Paykel Healthcare Ltd, Auckland, New Zealand.

This study is funded by the Institutional Budget and partly by the Fisher & Paykel Healthcare Ltd, Auckland, New Zealand.

MP and ST are employees of Fisher & Paykel Healthcare Ltd, the manufacturers of the nasal high flow (NHF) devices used in the study. TA has received funding and support from Fisher & Paykel Healthcare Ltd. All other authors have no declaration of interest.

The study is sponsored by the Nagasaki University Graduate School of Biomedical Sciences.

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
